Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson’s vast reach—spanning immunology breakthroughs, orthopedic implants, and everyday consumer staples—makes its SEC disclosures a gold mine of insight and a maze of technical detail. Drug-trial readouts, device recall costs, talc litigation updates, and dividend policy changes are scattered across hundreds of pages, prompting searches like “Johnson & Johnson SEC filings explained simply” and “Johnson & Johnson insider trading Form 4 transactions.”
Stock Titan’s AI decodes every document the moment it hits EDGAR. Whether you need the Johnson & Johnson quarterly earnings report 10-Q filing for segment revenue trends, a Johnson & Johnson annual report 10-K simplified view of risk factors, or a quick alert on Johnson & Johnson Form 4 insider transactions real-time, our platform extracts what matters. Key forms are mapped to practical insights:
- 10-K & 10-Q: pipeline progress, consumer health margins, R&D spend—ready for instant Johnson & Johnson earnings report filing analysis
- 8-K: product recalls and courtroom milestones with Johnson & Johnson 8-K material events explained
- Form 4: track Johnson & Johnson executive stock transactions Form 4 before market moves
- DEF 14A: explore Johnson & Johnson proxy statement executive compensation alongside peer benchmarks
Busy analysts, portfolio managers, and healthcare specialists use our AI summaries to cut reading time, monitor compliance events, and compare quarter-over-quarter performance. By understanding Johnson & Johnson SEC documents with AI, you can spot safety signals, verify dividend coverage, and gauge insider confidence—without sifting through 300-page PDFs. Real-time feeds, historical archives, and plain-language explanations ensure you never miss a disclosure that could shift your investment thesis.
Johnson & Johnson director John Morikis reported buying company stock. On 11/26/2025, he acquired 1,250 shares of common stock at a price of $206.15 per share, coded as transaction type "P." After this purchase, he beneficially owned 1,848.51 shares, held directly. The Form 4 indicates the filing relates to one reporting person and shows no derivative securities transactions.
Johnson & Johnson filed a Form 4 reporting small open-market sales of CVRx, Inc. common stock held indirectly through its subsidiary Johnson & Johnson Innovation - JJDC, Inc. JJDC sold 500 CVRx shares on 11/21/2025 at a price of $10.00 per share and 2,200 shares on 11/24/2025 at a weighted average price of $10.06 per share. After these transactions, Johnson & Johnson, through JJDC, indirectly beneficially owned 4,047,198 CVRx common shares. The filing notes that the 11/24/2025 price reflects multiple trades between $10.00 and $10.10, and Johnson & Johnson undertakes to provide detailed trade breakdowns upon request.
Johnson & Johnson filed a Form 4 reporting open‑market sales of CVRx (CVRX)52,332 shares at a weighted average price of $10.21 on 11/06/2025 and 200 shares at $10.00 on 11/07/2025. After these transactions, J&J indirectly beneficially owned 4,050,898 CVRx shares through JJDC. Prices for the 11/06 trades ranged from $10.00 to $10.49 per share.
Johnson & Johnson (JNJ) insider trade: EVP, Innovative Medicine, R&D, John C. Reed exercised 21,721 employee stock options at $157.92 per share and sold 21,721 common shares at a weighted average price of $192.7072 on 10/17/2025. Following these transactions, he directly beneficially owned 10,658 common shares and held 43,442 derivative securities (options). The sale price reflects multiple trades between $192.69 and $192.87.
Johnson & Johnson (JNJ) filed a Form 144 notice covering a proposed sale of 21,721 shares of common stock with an aggregate market value of $4,185,794.26. The filing lists an approximate sale date of 10/17/2025 on the NYSE through Fidelity Brokerage Services LLC.
The securities were acquired on 10/17/2025 via an option granted on 02/15/2024, with payment made on 10/17/2025 in cash. The notice states 2,408,338,872 shares outstanding. Over the past three months, John C. Reed sold 19,137 shares on 07/17/2025 for gross proceeds of $3,129,830.51.
Johnson & Johnson filed an 8-K announcing two updates. First, it issued a press release reporting sales and earnings for the third quarter ended September 28, 2025. Second, it announced its intent to separate the Company’s Orthopaedics business.
The filing notes the related exhibits: Exhibit 99.1 contains the Q3 2025 press release and Exhibit 99.2 provides unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the fiscal third quarter and nine months. Exhibit 99.3 contains the press release about the planned Orthopaedics separation. These disclosures were dated October 14, 2025.
John G. Morikis submitted an initial Form 3 disclosing beneficial ownership in Johnson & Johnson (JNJ). The filing reports direct ownership of 598.51 shares and indicates Mr. Morikis serves as a director of the issuer. The event requiring the statement is dated 09/08/2025 and the Form 3 was signed by an attorney-in-fact on 09/15/2025. The filing is an initial ownership disclosure under Section 16.
Marillyn A. Hewson, a director of Johnson & Johnson (JNJ), acquired 280.788 Deferred Share Units (DSUs) on 09/09/2025 under the company's Amended and Restated Deferred Fee Plan for Directors. The DSUs were recorded at a per-unit value of $178.07 and will be settled in cash upon termination of the reporter's directorship. The reported DSUs include accrued dividend equivalent rights tied to the issuer's quarterly dividend. Following the transaction the reporting person’s total DSU exposure is shown as 13,816.8727 units.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
